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A B S T R A C T   
Breast reconstruction is rapidly evolving, thanks to the growing acceptance of synthetic meshes as innovative 
biomaterials. 276 patients undergoing mastectomy (total of 328 mastectomies) were analyzed in a retrospective 
observational study to evaluate the pre-pectoral immediate breast reconstruction (IBR) using an implant 
wrapped with Titanium-Coated Polypropylene Mesh (TCPM) vs. patients treated with tissue expander (TE), 
equally placed pre-pectorally (and wrapped with the same TCPM in 74.3% of the control group’ breasts). 163 
patients, of the study group (SG), underwent mastectomy and pre-pectoral IBR with implant wrapped with 
TCPM, in a one-step surgery, called direct-to-implant technique (DTI), while 113 patients control group (CG) 
underwent mastectomy and TE. DTI technique has been performed in 192 breasts of the SG while TE procedure 
in 136 breasts of the CG. The BREAST-Q questionnaire has been provided before the treatment and 2 years later. 
Baker scale has been used to evaluate capsular contracture. Oncologic, surgical, and aesthetic outcomes along 
with BREAST-Q scores were analyzed. Additionally, a histologic evaluation was conducted in 11 capsules’ 
samples randomly chosen (6 derived from SG patients and 5 derived from CG). Complications were recorded in 
43 cases (29SG-14CG): 8 skin-nipple necrosis (5SG-3CG), 8 wound dehiscence (6SG-2CG), 3 hematomas (1SG- 
2CG), and 24 infections (8SG-16CG). Grade IV capsular contracture was detected in 9 breasts (1SG-8CG), 
whereas 254 breasts were grade I (110SG-144CG), 33 (10SG-23CG) grade II, and 32 (4SG-28CG) grade III. 
Implant wrinkling was detected in 18 cases (10SG-8CG) after 30 months. The local tumor recurrence rate was 
5.8%. Three recurrences were on the nipple-areola complex (1.9%). SG patients showed significantly higher rates 
in the BREAST-Q overall Satisfaction with Outcome (74.1), overall Satisfaction with Breasts (69.1), Psychosocial 
Well-being (81.9), and Sexual Well-being (63.1), versus CG’s patients (p < 0.05). Histological analysis showed a 
process of normal tissue repair with a complete mesh integration and normal healing. Conservative mastectomies 
with pre-pectoral IBR assisted by TCPM proved themselves oncologically safe, biologically integrated into native 
tissues, and highly accepted in terms of quality of life guaranteeing a more natural and aesthetic breast 
appearance. 
Core tip: This retrospective observational study provided clinical and histological outcomes of the pre-pectoral 
IBR using an implant wrapped with TCPM vs. patients treated with TE, equally placed pre-pectorally. The ef-
ficacy of IBR using an implant wrapped with TCPM was confirmed by the cosmetic results obtained and by a rate 
of side effects comparable to TE. All the histological analyses performed confirmed the TCPM mesh complete 
integration with the physiological aspects of healing: The Collagen 1 and 3 expressions did not differ, between 
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TCPM and NO TCPM samples to confirm a process of healing overlapping to perfect device incorporation and 
normal healing.   
1. Introduction 
Skin-Sparing Mastectomy (SSM) or Skin-Reducing Mastectomy 
(SRM) and Nipple-Sparing Mastectomy (NSM), often called conservative 
mastectomies, can be all considered oncoplastic surgery developments 
born with Veronesi U [1]. Meta-analyses investigations displayed that 
SSM and NSM results do not differ from those for non-conservative 
mastectomies [2]. Recurrence rates in the nipple-areola complex 
(NAC) after NSM are acceptably low (0–3.7%) [2], additionally the 
psychological adjustment and patient satisfaction rate are good in peo-
ple who underwent NSM [3]. The principal side effect of NSM is NAC 
necrosis, and factors promoting it are large breasts, breast ptosis, 
radiotherapy, smoking, and obesity [2,3]. For patients needing mas-
tectomy, NSM should be the first choice [3]. 
Carlson et al. [4] reported 4 different types of SSMs: types I to III for a 
small breast with a low ptosis degree using a peri-areolar approach; type 
IV for a large breast with high ptosis degree plus breast reduction of the 
contralateral breast. The introduction of the SRM concept, based on 
permanent implant positioning into a large pocket made by the pec-
toralis major muscle and an inferior pedicle dermal flap, allows 
obtaining a safe oncologic result with a cosmetically satisfying recon-
struction [5]. Conservative mastectomies entail both cancer removal 
and preparation of skin flaps, usually allowing an immediate breast 
reconstruction (IBR) and breast reshaping to provide better aesthetic 
outcomes, without compromising local disease control [6]. The most 
important advantage of IBR is to avoid the necessity of repeated several 
surgical procedures to restore breast profile. 
Breast reconstruction can be based on autologous tissue or prosthesis 
which could be positioned immediately or in two stages (tissue expander 
and prosthesis). Different techniques of breast implant positioning 
(subcutaneous, sub-muscular, dual-plane) were pioneered in the last 
decades. 
Snyderman and Guthrie [7] in 1971 reported the subcutaneous 
placement of implants as the first attempt in prosthetic reconstruction. 
This procedure, however, was associated with a high rate of side effects, 
such as mastectomy skin flap necrosis, prosthesis extrusion, and capsular 
contracture [8,9]. Subsequently, Gruber et al. [10] and Argenta et al. 
[11] reported superiority of a reconstruction performed with a 
sub-muscular prosthesis (described as retro- or sub-pectoral) over the 
subcutaneous to improve the aesthetic outcomes and reducing the side 
effects rate [10,11]. As the sub-pectoral pocket left after mastectomy 
was assumed to be too small to accommodate an implant, many sur-
geons opted, in the past, for the two-stage sub-muscular implant-based 
breast reconstruction. 
The introduction of biomaterials as biological and/or synthetic 
matrices opened new scenarios in prosthetic-based breast reconstruction 
(PBBR). A combined partly sub-muscular and partly sub-matrix dual- 
plane implant pocket has now become the standard of care. These 
matrices provide the opportunity of enlarging the sub-muscular pocket 
thus allowing adequate prosthesis coverage for a definitive PBBR in one- 
step surgery, the so-called direct-to-implant technique (DTI) [12–18]. 
The idea of totally wrapping the implant with these matrices acting 
as bioactive materials, resurrected the concept of a total pre-pectoral 
approach in breast reconstruction, allowing a more natural prosthesis 
positioning in the subcutaneous plane [14–18]. This procedure was 
introduced in 2014 positioning the prosthesis in a subcutaneous pocket, 
wrapped by a titanium-coated polypropylene mesh (TCPM) [10]. 
Additionally, two investigations showed the preliminary outcomes of a 
pre-pectoral DTI reconstruction, with prosthesis wrapped by a biological 
a-cellular dermal matrix (BADM) [16,17]. 
A recent study of Casella et al. [19] displayed the long-term results of 
TCPM, (wrap-around technique after mastectomy and sub-cutaneous 
DTI breast reconstruction), reporting the BREAST-Q evaluation. 
The rationale for the present investigation and of a pre-pectoral 
reconstruction performed with TCPM is this device may replicate in a 
sub-cutaneous approach, the same coverage effect of muscles in the 
retro-pectoral technique, without any muscular detachment. The au-
thors’ effort has been to confirm the assumption that a sub-cutaneous - 
pre-pectoral reconstruction using soft tissue replacement bioactive ma-
terials, as TCPM mesh, is feasible, safe, and giving more rewarding 
outcomes particularly when it is done in a one-step (DTI) approach. 
Moreover, a biomaterial is considered bioactive when it is able to inte-
grate into the host tissue through physiological and controlled reactions. 
Therefore, the aim of the present work was also to demonstrate, 
through the histological analysis supported by immunofluorescence and 
immunochemistry, the physiological incorporation of the synthetic 
TCPM mesh after pre-pectoral immediate breast reconstruction. 
2. Methods 
2.1. Study overview and data definitions 
This observational case-controlled study was conducted following 
the principles outlined in the Declaration of Helsinki, as revised in Tokyo 
in 2004 and internationally consented ethics in clinical research [20]. A 
quality assessment was carried out based on the STrengthening the 
Reporting of Observational Studies in Epidemiology (STROBE) checklist 
[21]. The study protocol was previously approved in 2011, as already 
reported [15,19], by the Institutional Ethics on Research Committee of 
the University-Hospital, “Careggi” Florence, Italy. Additionally, the 
protocol has been performed following the European rules 
726/2004/EC, 2001/83/EC, 2001/82/EC, and 2001/20/EC. Also, the 
study was subject matter of a research contract (R.D. #1467/2017) and 
associate professor contract (R.D. #13489/2021) between the first 
author P.G., and the University of Rome, “Tor Vergata”. All patients 
signed an informed consent form, before any surgical treatment, in 
which detailed information about the study, including the risks, bene-
fits, and alternative therapies, has been reported. 
2.2. Patient population 
Between January 2012 and December 2018, 590 females undergoing 
mastectomy were enrolled, of which, 276 were assessed for eligibility. 
328 interventions were performed in the assessed population. Patients 
and mastectomies assessment were shown in a CONSORT flow diagram 
(Scheme 1). 
Inclusion and exclusion criteria were considered. The inclusion 
criteria were indication to NSM, SSM and SRM either therapeutic or 
prophylactic, age 25–85 years old, and BMI 16–40. On the other hand, 
exclusion criteria were T4 and metastatic cancer, refusal to sign the 
specific informed consent, uncontrolled comorbidities or multiple 
comorbidities (three or more among diabetes, renal failure, heart fail-
ure, cardiovascular diseases, hypertension, pulmonary diseases, hepatic 
diseases and metabolic diseases). The presence of only one or two 
comorbidities (in particular diabetes and/or hypertension), were not 
considered exclusion criteria. Smoking, previous radiotherapy and 
chemotherapy were not considered exclusion criteria. Equally, previous 
breast surgery was not considered exclusion criteria. 
All enrolled patients were undergoing a full preoperative screening, 
including a complete clinical examination, photographic, and cancer 
assessments. Before surgery, all patients were evaluated for both 
autologous or alloplastic breast reconstruction, taking into account 
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Scheme 1. CONSORT (Consolidated Standards of Reporting Trials) flow diagram on patients’ enrollment, including mastectomies and treatments assessment.  
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patient preference, body habitus, comorbidities, and surgeon experi-
ence. Baseline characteristics were listed in Table 1 while Table 2 listed 
the characteristics of the surgical procedures. 
Post-mastectomy flaps were always evaluated as adequate, and no 
reconstruction was aborted. The conservative mastectomy with sub- 
cutaneous DTI pre-pectoral reconstruction in one-step surgery, assisted 
by TCPM mesh, has been performed in 163 patients -Study Group- (SG), 
treating 192 breasts (58.5%) while TE pre-pectoral procedure has been 
done in 113 patients -Control Group- (CG), treating. 
136 breasts (41.5%), followed by a second step represented by the 
tissue expander changing with a definitive implant. Breasts of the CG 
patients were divided into two subgroups: CG′ breasts treated using TE 
wrapped with TCPM (n = 101) and CG’ breasts who underwent TE 
without TCPM (n = 35). 
The size of the implants used both during DTI and after TE changing 
with definitive prostheses was between 270 and 470 cc, while the size of 
the TE was between 250 and 500 cc. The choice of the definitive pros-
thesis (both anatomical and round) was performed based on the tissues 
available, with “custom made” methods. 
The average tumor size was 31.8 mm (range, 0–82 mm). The drain 
was removed between the second and ninth postoperative days (mean, 
4.2 days). The definitive pathology report was invasive ductal carci-
noma in 153 cases, ductal carcinoma in situ in 23 cases, invasive lobular 
carcinoma in 6 cases, and ductal carcinoma in situ with foci of invasive 
ductal carcinoma in the remaining cases. Tumor-related data are sum-
marized in Table 2. 
The choice to perform a DTI reconstruction or a TE reconstruction 
has been done by the single-center Multi-Disciplinary Team (MDT)’s 
oncological and reconstructive guidelines and determined by the patient 
characteristics and preferences. Thin patients, with emaciated and 
stretched skin were not considered eligible candidates to DTI. Equally 
obese, hypertensive and diabetic patients and smokers were not 
considered good candidates as well, due to of a compromised micro-
vascular performance of their skin flap. The features of treated patients 
were reported in Table 1. 
Post-operative follow-up was scheduled at 2, 7, 15, 21, and 36 weeks 
and then annually for five years. 
2.3. Clinical data assessment 
Data have been prospectively sign-in a database using SQTM® 
software (CPO, Turin, Italy), an application designed for the breast 
Table 1 
Baseline characteristics of the patients included in the analysis.  
Characteristics  Patients 




Age Mean 55  54 56  
SD ±10.33  ±10.11 ±10.55  
Range (26–84)  (26–82) (28–84) 
BMI Mean 28  27 29  
SD ±4  ±3.85 ±4.25  
Range (16–40)  (16–38) (18–40) 
Smoke No 231 83.7% 133 98  
Current 45 16.3% 26 19 
Hypertension No 228 82.6% 123 105  
Yes 48 17.4% 36 12 
BRCA 
mutation 
No 254 92.0% 149 105  
Yes 22 8.0% 10 12 
Diabetes No 268 97.1% 155 113  
Yes 8 2.9% 4 4 
Previous RT No 237 85.9% 137 100  
Yes 39 14.1% 22 17 
Mastectomy Bilateral 47 17.0% 28 19  
Bilateral in 
second time 
5 1.8% 2 3  
Unilateral 224 81.2% 129 95  
Table 2 





Mastectomy Prophylactic 61 18.6%  
Therapeutic 267 81.4% 




SRM - Nipple Sparing 10 3.0%  
SRM- No Nipple 
Sparing 
7 2.1%  
SSM 65 19.8% 
Previous Surgery 1 = Wide Excision 
Unilateral 
34 10.4%  
2 = Wide Excision 
Contralateral 
5 1.5%  
4 = QUART Unilateral 34 10.4%  
5 = QUART 
Contralateral 
7 2.1%  
6 = Breast 
Augmentation 
7 2.1%  
7 = Contralateral 
Mastectomy 
22 6.7%  
8 = None 219 66.8% 
Axilla SNB Final 102 31.1%  
SNB Intraoperative 
Negative 
77 23.5%  
SNB + Axillary 
Dissection 
22 6.7%  
SNB + Axillary 
Dissection Delayed 
15 4.6%  
Axillary Dissection 37 11.3%  
No 75 22.9% 
Cutting Linear 59 18.0%  
Periareolar 21 6.4%  
S in External Quadrants 200 61.0%  
Inframammary Fold 10 3.0%  
Inverted T 36 11.0%  
Vertical 2 0.6% 
Radiotherapy No adjuvant 278 85.0%  
Yes adjuvant 49 15.0% 
Chemotherapy Adjuvant 93 28.4%  
Neo-adjuvant 30 9.1%  
No 205 62.5% 
Hormone 
Therapy 
No 138 42.2  
Yes 189 57.8 
Trastuzumab No 277 84.7  
Yes 50 15.3 
Device Prosthesis (DTI) 192 58.5  
Expander (TE) 136 41.5 
pT T0 79 24.1  
Tis 44 13.4  
T1 156 47.6  
T2 47 14.3  
T3 2 0.6 
pN N0-X 251 76.4  
N1 52 15.9  
N2 13 4.0  
N3 12 3.7 
ER – 30 9.1  
+ 214 65.2  
Not performed 84 25.6 
PgR – 52 15.9  
+ 192 58.5  
Not performed 84 25.6 
Ki67 <20% 79 24.1  
>20% 130 36.9  
Not performed 119 36.3 
Her 2 Amplified 51 15.5 
Lymph-nodes 
invasion 
Absent 145 44.2  
Present 56 17.1  
Missing 127 38.7  
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cancer therapy’ quality control. The following characteristics were 
prospectively recorded in the dataset: demographic data, age, BMI, 
histological evaluation, surgical and oncological management, surgical 
complications, time and site of recurrence, adjuvant or previous radio-
therapy, and chemotherapy data. All the therapeutics options were 
discussed and decided by an MDT, including a breast surgeon, a plastic 
surgeon, a pathologist, a radiologist, an oncologist, a radiotherapist, and 
a psycho-oncologist. 
During the first five years, patients were followed up every six 
months by clinical examination and oncological examinations as 
required and every twelve months by surveillance mammogram and 
ultrasound (US) or magnetic resonance imaging (MRI) if needed. Re-
currences were documented by clinical examination, radiological tests, 
and pathological assessment. Local and distant recurrence rates evalu-
ation were additional end-points of the study and were evaluated as the 
oncological safety outcome. 
The primary end-points of the study were the clinical outcomes. They 
were: the incidence of perioperative and postoperative complications 
(safety profile), quality of life (QoL) at 2 years after surgery, measured as 
the change between the pre-operative and post-operative BREAST-Q 
scores (questionnaire on Satisfaction with Breasts, Satisfaction with 
Outcome, Psychosocial Well-being, Physical Well-being, and Sexual 
Well-being, post-operative questionnaire was administered after second- 
stage surgery in case of TE reconstruction), the aesthetic outcome 
(assessed by an independent panel of plastic surgeons, based on stan-
dardized photographs taken two years after surgery in DTI cases and 
after two years from second stage in TE cases) and the capsular 
contracture grade, assessed by a panel of plastic surgeon through 
outpatient clinic visits. 
The Surgical-team aesthetic evaluation was an objective evaluation 
based on clinical assessment, using a scale of six degrees (excellent, 
good, discreet, enough, poor, inadequate). 
At every evaluation degree was assigned a single numeric unit score 
to be summed-up for a final score for each patient considering the 
following variables: breast volume, shape, position of infra-mammary 
fold, and scars. 
All adverse events were recorded for two years after breast recon-
struction. Surgical complications were classified as those requiring a 
surgical re-treatment, including skin-nipple necrosis, seroma, wound 
dehiscence, wound infection, and hematoma. Such reinterventions 
consisted in a revision surgery when possible or in the implant/TE 
removal when necessary (failure cases). Other surgical interventions 
performed purely for aesthetic purposes were considered separately in 
the statistical analysis. The Baker scale was used for scoring capsular 
contracture during postoperative follow-up. 
Moreover, as a secondary end-point of the study, a histopathological 
assessment of the capsule was performed, to evaluate the integration of 
the TCPM in the mastectomy flap as a bio-active material. 
2.4. Surgical protocol 
Surgical incisions (Fig. 1A, representing an SRM-NS) were done ac-
cording to the surgeon’s experience, his preference, and to the type of 
conservative mastectomy chosen. Sentinel lymph-node/s biopsy and 
axillary surgery, when needed, were performed according to the single 
oncological requirements. The choice of SSM, NSM, or SRM mastectomy 
was carried out following the surgical oncology criteria and according to 
breast volume and ptosis. Medium or small breast (cup size A–B, 
200–500 g) with < 8 cm of NAC-inframammary fold distance, no more 
than grade 1 ptosis according to the Regnault classification, patients’ 
desire of breast reconstruction with a volume no larger than the pre-
operative one, were considered selective criteria to perform a DTI after 
NSM. A pre-operative evaluation of the subcutaneous breast tissue or 
“gland envelope” thickness, represented by the distance between the 
skin and the gland through a digital mammogram has been performed. 
Pre-operative digital mammogram, as suggested by Rancati et al. [41], 
allows an accurate evaluation of the breast coverage and a preview of 
the resulting flap thickness, with a consequent possible prevision of flap 
quality and vascularization. Therefore, the patients’ selection candidate 
to DTI has been additional performed favoring those with breast sub-
cutaneous tissue coverage above 2 cm at pre-operative digital 
mammography (type 3 according to Rancati score [41]), as to obtain an 
Fig. 1. Intra-surgical view of a bilateral SRM-Nipple Sparing, with TCPM mesh use, and re-grafting of NAC according to Thorek technique. A) Surgical incision 
during SRM according to Wise pattern. B) Dermal-skin flap preparation. C) Prosthesis placement under the TCPM mesh. D) Skin flap positioning down over the 
prosthesis and mesh. E) NAC re-implanting as a free graft according to the Thorek technique and its fixation over the skin flap. F) Final sutures and contralateral 
identical procedure in a bilateral SRM for a BRCA mutation in a very large and ptotic breast. Clinical cases and outcomes were shown in Fig. 2. 
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adequate flap after NSM, represented by the distance between the su-
perficial layer of the fascia superficialis (the mastectomy “safe” surgical 
plane) and the skin. At the end of mastectomy, skin flap viability 
(Fig. 1B) and the confirmation of a sub-cutaneous pre-pectoral recon-
structive approach were left to the evaluation of the operating onco-
plastic surgeon. Muscles, pectoralis major and serratus, were not 
dissected at all in both DTI procedures and TE reconstructions. Partial 
resection of pectoralis major muscle was allowed, as needed, only if 
cancer’s infiltration was confirmed. 
2.5. Breast reconstruction options: DTI reconstruction using prosthesis 
and mesh 
During DTI reconstruction, the TCPM (Fig. 1C), here called “sup-
portive material” and the prosthesis were prepared for implantation via 
two different modes: the prosthesis was completely wrapped by the 
TCPM or, it was covered only on its anterior profile. In the first case, a 
purse-string suture on three sides of the supportive material sheets was 
adopted to create a “bag” around the prosthesis itself. In the case of 
larger implants, two TCPM sheets were sutured together along three 
sides to create a pocket where the implant will have been positioned 
from the opening. The supportive material will have to be tightly 
enfolded around the prosthesis with just a few loose ends of excessive 
material on the upper border. 
After being washed with an antibiotic solution of Gentamicin, the 
implant and the TCPM were inserted on the mastectomy site. Once the 
appropriate orientation of the prosthesis had been verified, TCPM was 
secured using two interrupted stitches between the muscular fascia and 
the upper border of the supportive material, one on the sternal edge and 
the other one on the axillary anterior line. 
In the second case, the prosthesis was covered only on its anterior 
profile. In such circumstances TCPM was transferred on the mastectomy 
site and secured to the muscular fascia, with few interrupted stitches, to 
cover the upper border of the prosthesis in first place. Afterward, the 
implant was placed under the supportive material (Fig. 1C), which, like 
a tent, was stretched to tightly cover the implant. With everything in 
place, the operator secured the inferior border of the supportive mate-
rial, with few interrupted stitches, to keep it tightly folded around the 
prosthesis lower pole. At this point, the skin flap was stretched down 
(Fig. 1D), and a free graft NAC repositioning was performed (Fig. 1E). 
Contralateral breast mastoplasty (either augmentation, mastopexy or 
reduction mastoplasty) was performed where indicated or a bilateral 
identical procedure was performed in case of bilateral mastectomy 
(Fig. 1F). 
2.6. Breast reconstruction options: TE reconstruction in combining with 
mesh 
During the TE-reconstruction based on two steps, once a right size 
expander was chosen, the TE was prepared with the supportive material 
TCPM in two different ways, as previously described for DTI: the TE was 
completely wrapped by TCPM or it was covered only on its anterior 
profile. The wrapping procedures of TCPM may be considered as totally 
overlapping to those of DTI. In the case of larger expanders, as in larger 
prostheses during DTI, two TCPM sheets were sutured together along 
three sides to create a pocket where the implant will be positioned from 
the opening. When wrapping a TE, differently to DTI, the supportive 
material will have to be loosely enfolded around the expander with 
enough space left for future expansions, even though using a re- 
absorbable suture to fix the mesh an easy expansion of the mesh itself 
along with the TE is guaranteed after few weeks. During the second step 
of TE exchange for the implant, a moderate capsulotomy was performed 
only where necessary, but a complete capsulectomy was not permitted, 
being the integrated supportive material an essential cornerstone of the 
pre-pectoral approach, recreating a new fascia. 
For each patient, both SG and CG, the surgical incision was sutured 
after excising a 2 mm wide skin stripe on both sides of the incision itself. 
At least two layers of sutures were performed. 3–0, 4–0, and even 5- 
0 monofilament re-absorbable sutures were applied depending on the 
surgeon’s preference. Both interrupted and running sutures were 
allowed. 
2.7. Clinical evaluation of aesthetic outcomes: primary endpoints 
Two methods for the clinical analysis of the results, primary end-
points of the study have been used: Surgical-Team-evaluation and pa-
tient self-evaluation. The Surgical-team evaluation was an objective 
evaluation based on clinical assessment, using a scale of six degrees 
(excellent, good, discreet, enough, poor, inadequate). The subjective 
patient-based self-evaluation applied the same six degrees. Breast vol-
ume, breast shape, position of infra-mammary fold, and scars were 
evaluated. 
2.8. Histological evaluation and secondary endpoints 
As a secondary endpoint of the present study, a histological assess-
ment was conducted to evaluate the outcomes of TCPM mesh tissue 
integration both in DTI and TE procedures, with biopsies taken intra-
operatively during reinterventions for SG cases and second-stage oper-
ations for CG. Hematoxylin-eosin staining of post-operative biopsies of 
wrapping tissue TCPM mesh was performed focusing on the collagen 
presence and fibroblasts amount and specifically, on the complete 
healing and TCPM incorporation without side effects. 
Additionally, the immunofluorescence using specific markers CD 45 
and Collagen 1, and immunohistochemistry using CD 45 on paraffin 
samples were performed. 
The endpoint was to evaluate the grade of inflammation represented 
by the number of lymphocytes in the treated site, and the eventual 
different collagen type expression (Collagen 1 and Collagen 3) in tissues 
which underwent or not to radiotherapy and during or not the use of 
TCPM. 
2.9. Histological and bio-molecular analyses of mastectomy flap biopsies 
The biopsies of the mastectomy flaps previously undergone to sub- 
cutaneous pre-pectoral DTI and TE reconstruction were obtained from 
11 patients randomly chosen (called 1A, 1B, 2A, 2B, 3A, 3B, 3C, 4A, 4B, 
4D, 5) (Scheme 1), six derived from SG patients who underwent DTI 
with TCPM mesh (three treated with radiotherapy and three radio free), 
and five derived from CG patients treated with TE (two treated with 
TCPM and radiotherapy and three not treated with TCPM and radio 
free). Biopsies were all performed in a time span between 12 and 24 
months after the surgical procedures. The punch biopsies were all per-
formed during a further surgical procedure under general anesthesia at 
the moment of TE exchanging with definitive implants in CG (two-stage 
reconstructions), while they were performed during a second operation 
in SG’s patients who underwent DTI. The anatomical part of the breast 
chosen to be punched was different according to the type of mastectomy 
performed, and the skin incision but in each case, it was performed in 
the proximity of the scars (to obtain invisible outcomes) harvesting 
samples of neo-fascia. Antibiotic prophylaxis was performed in all cases. 
11-μm paraffin sections were stained with Hematoxylin and Eosin for 
histological analysis. Three slides for each patient were carefully 
analyzed 10x and 40x high power fields to investigate the number of 
lymphocytes, collagen, and fibroblast amounts. In parallel, immuno-
fluorescence was introduced to evaluate the different Collagen 1 and 3 
expressions inside all of the tissue undergone TCPM ± radiotherapy and 
in tissue free from TCPM ± radiotherapy. 
A scoring system was elaborated to quantify the percentage of 
Collagen 1 and Collagen 3. A score of 200, 400, 600, 800, or 1000 was 
assigned to the area that was covered by each type of collagen identified 
as a proportion of the entire area of every single slide analyzed. 
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Subsequently, the average score of all slides for the eleven patients was 
calculated. 
2.10. Patient selection for capsule biopsy 
The patient’s choice, relating to the biopsy selection, was created 
with the use of an online randomization generator (https://www.rando 
mizer.org) among all the SG and CG patients undergoing a second 
operation after mastectomy and turned into concealed entities through 
someone unrelated to the trial. The participant histology assessors were 
all blinded to the type of surgery, and blinding was maintained until all 
information had been analyzed. 
2.11. Statistical analysis 
Using the Q Score Scoring Software, BREAST-Q scores were con-
verted from survey raw scores (1 through 4 or 5) to a continuous range 
from 0 to 100, with a higher score representing greater satisfaction or 
better health-related quality of life. The scores for each BREAST-Q ma-
trix index were determined at each time point and then entered into the 
database, along with the other data collected from patients and medical 
records. Both absolute BREAST-Q scores and their changes before and 
after treatment were analyzed. The Shapiro-Wilk test was used to verify 
for normal distribution of continuous variables. Consequently, BREAST- 
Q scores and panel scores were analyzed as continuous variables using 
the t-test. Values of p < 0.05 were considered statistically significant. A 
comparison of clinical and biological characteristics between the pa-
tients was performed by the Kruskal Wallis rank test for continuous 
variables and Pearson’s Chi-square test (or Fisher’s exact test when 
appropriate) for categorical variables. Logistic regression was used to 
investigate which factors were associated with recurrence events, either 
loco-regional or systemic. Independent variables of interest were sur-
gical technique, age above 50 years old, lymph-vascular invasion, 
oncological stage, adjuvant or neoadjuvant chemotherapy, adjuvant 
radiotherapy, and adjuvant hormone therapy. Multiple logistic regres-
sion analyses were performed to account for several confounding vari-
ables simultaneously and included all variables of interest. 
3. Results 
3.1. Safety and oncological outcomes 
The average post-surgical follow-up period was 44 months (range, 
23–65 months). Complications were recorded in only 43 cases (13.1%) 
of which 29 cases (67.4%) belonged to the SG and 14 cases (32.6%) to 
the CG. To have a better comprehension of the outcomes it is necessary 
to consider that the SG comprised 159 patients, while the CG 112. In this 
way, the percentage of complications in SG was 18,3% versus 12,5% of 
the CG, where the SG was bigger by 42% than the CG (47 patients more 
versus CG). 
These complications recorded in 43 cases were:  
- Skin-nipple necrosis (8 cases), of which 5 in SG and 3 in CG;  
- Wound dehiscence (8 cases), of which 6 in SG and 2 in CG;  
- Hematoma (3 cases), of which 1 in SG and 2 in CG;  
- Infection (24 cases), of which 8 in SG and 16 in CG. 
Analyzing the side effects with the use of t-test, the complication rate 
between SG and CG did not shown statistically significant differences (p 
= 0,8472), although it was slightly higher in the SG. 
Despite the study group being bigger than the control group (+42%) 
the side effects’ number did not statistically differ, confirming the safety 
and reliability of the TCPM procedure during DTI. 
A second operation was performed in all of these cases, and in 15 
cases implant/TE removal was required (4.6%), followed by recon-
struction with sub-muscular expanders in all cases. In 7 cases of 
infection, the authors removed only the implant without removing the 
wrapped-around matrix pocket, successfully clearing the infection. 5 
patients who underwent prophylactic NSM and DTI reconstruction had 
positive ductal carcinoma in situ, in the retro-areolar tissue, at final 
histology. In these cases, the excision of the NAC was performed; none of 
these patients experienced the loss of the implant, and they all main-
tained the reconstructed breast. Safety profile and oncologic outcomes 
are summarized in Table 3. 
Two years after surgery, grade IV capsular contracture was detected 
in 9 breasts (1 in SG and 8 in CG), whereas 254 breasts were evaluated as 
grade I (110 in SG and 144 in CG), 33 breasts (10 in SG and 23 in CG) 
were evaluated as grade II, and 32 breasts (4 in SG and 28 in CG) were 
evaluated as grade III. The total rate of significant (Baker III to IV grade) 
capsular contracture was reported as low as 12.5%. Patients who re-
ported grade IV capsular contracture had all undergone adjuvant 
radiotherapy in the post-operative period. In case of severe contracture, 
implant replacement was required and was performed after an average 
of 28 months. Implant wrinkling was detectable in 18 cases (10 in SG 
and 8 in CG) after 30 months, and two or three fat grafting procedures 
were performed, successfully reducing implant visibility. The average 
fat volume injected was 73.3 ml per breast in each fat grafting session. 
The local tumor recurrence rate was 5.8%. Three recurrences were on 
the NAC (1,9%), two recurrences in axillary lymph-nodes (1,3%), three 
recurrences in skin flap (1,9%) and one recurrence (0,7%) in the muscle. 
The median time of loco-regional recurrence appearance was 21 months 
(range, 8–37 months). All risk factors for early complications and risk 
factors for failures were reported in Table 4 and Table 5 respectively. 
3.2. The measure of health-related quality of life 
213 patients adequately responded to the domains of the BREAST-Q 
questionnaire. A comparison between pre-operative and post-operative 
(2-year follow-up) self-reported scores was analyzed. Overall Satisfac-
tion with Breasts, Psychosocial Well-being, and Sexual Well-being scores 
were all significantly increased after sub-cutaneous pre-pectoral DTI 
immediate reconstruction with TCPM mesh (p < 0.05) compared to CG. 
Patients scored a high level of Overall Satisfaction with Outcome index, 
measured postoperatively. The 15 patients who underwent prosthesis 
removal (either implant or TE) for wound dehiscence and infection re-
ported lower post-operative scores compared to the average in the self- 
reported measures of Overall Satisfaction with Outcome (74.1), Overall 
Satisfaction with Breasts (69.1), Psychosocial Well-being (81.9), Sexual 
Well-being (63.1), and Physical Impact (79.2). The 15 patients scored a 
moderate increase from the baseline in all of the domains, except for 
Sexual Well-being and Physical Impact measures, which were decreased 
postoperatively. In any event, these changes were not statistically 
significant. 
3.3. Clinical aesthetic outcomes 
High scores, for breast volume, breast shape, position of infra- 
mammary fold, and scars were reported post-operatively. Mean satis-
faction with the overall aesthetic result was high after breast recon-
struction (8.72) in patients who underwent DTI pre-pectoral immediate 
reconstruction (SG) after 2 years from surgery (Fig. 2A–F). Aesthetic 
outcome scores are as follows: symmetry, 3.8; shape, 4.1; scars, 4.3; 
volume, 4.4; the position of the infra-mammary fold, 4.1; and overall 
evaluation score, 8.4. 
3.4. Histological analysis 
As known, the breast tissue may be distinguished in several different 
layers, such as the epidermis and derma (superficial layer), the subcu-
taneous tissue containing fat and gland (intermediate layer), and mus-
cles (deep layer) as graphically shown in Fig. 3A. These layers were 
displayed well in Hematoxylin-eosin staining of post-operative biopsies 
P. Gentile et al.                                                                                                                                                                                                                                  
Bioactive Materials 6 (2021) 4640–4653
4647
(Figs. 3B and 4A). 11 patients and related samples were selected with 
simple randomization (randomly). The allocation sequence has been 
created using an online randomization generator (https://www.rando 
mizer.org) and has been concealed by a person unrelated to the trial 
management group. 
In this series, tissue’ fragments incorporating TCPM mesh were 
analyzed (Fig. 3C). Collagen and fibroblast were identified, displaying 
complete incorporation of the mesh with physiological aspects of heal-
ing (Figs. 3D and 4B). 
3.5. Bio-molecular assessment of mastectomy flap biopsies 
The immunofluorescence using CD 45+ and Collagen 1 (Fig. 5A–D), 
was performed in irradiated tissue treated with TCPM mesh (Fig. 5A and 
B) and in tissue that was not treated with radiotherapy and that was not 
reconstructed using TCPM (Fig. 5C and D). Fig. 5A and also Fig. 5B 
displayed a higher concentration of lymphocytes (red arrows) compared 
to Fig. 5C and D. 
The immunohistochemistry using CD 45+ on several paraffin sam-
ples displayed (Fig. 6A and B) the presence of lymphocytes (red arrows) 
and fibroblasts (blue arrows) around the TCPM mesh in irradiated tissue. 
The bar graph displayed in Fig. 7A–D analyzes the differential 
expression of Collagen 1 (Fig. 7A and C) and Collagen 3 (Fig. 7B and 7D) 
concluding that Collagen 1 and 3 expression is the same (no statistical 
difference was observed) between TCPM and NO TCPM samples while is 
higher in samples of patients who didn’t undergo radiotherapy (p < 0.05 
vs. radio). 
All the analyses performed confirmed the presence of inflammation 
in irradiated tissue as revealed by the high number of lymphocytes and 
also the complete integration of the TCPM mesh with physiological as-
pects of healing. In detail, the Collagen 1 and 3 expressions did not 
differ, with statistical significance, between TCPM and NO TCPM sam-
ples to confirm a process of healing demonstrating a perfect device 
incorporation and normal healing. Contrarily, the higher expression of 
Collagen 1 and 3 in tissue free from radiotherapy confirms the better 
quality of the subcutaneous layer of these tissues over radiotherapy 
tissues. 
4. Discussion 
Complications of conservative mastectomies with immediate 
implant-based reconstruction include infections, wound dehiscence, and 
implant loss, capsular contractures, asymmetries, and deformities with 
poor QoL results [22,23]. 
In patients who underwent NSMs, flap necrosis and NAC necrosis 
also may be considered relatively common complications. Headon et al. 
[24] conducted a pooled analysis of 12,358 NSMs to evaluate the 
adverse events and related oncological safety. The overall adverse 
events rate was 22.3% and the NAC necrosis rate was 5.9%. In this study, 
it is necessary to highlight that the rates of adverse events, including 
NAC necrosis, decreased over time, which was attributed to the 
improvement of the surgeon’s expertise. They had reported that the 
factors predisposing to NAC necrosis were big and ptotic breasts, smoke, 
peri-areolar incision, and previous radiotherapy. 
An investigation of the European Institute of Oncology [25] reported 
that comorbidity, smoke, incision type, flap thickness, and re-
construction’s choice all influenced the NAC necrosis rate in NSMs. 
PBBR is the most frequent reconstructive choice nowadays mostly in 
the case of conservative mastectomies like NSM [26,27]. In the early era 
of PBBR, sub-cutaneous prosthesis positioning represented the first 
approach, as reported by Snyderman in 1971 [28]. Subsequently, also 
the pioneers of TE, Radovan, and Lapin, adopted a sub-cutaneous 
positioning of their expanders [29,30]. By that time, however, most of 
the reconstructions were considered and performed in the setting of a 
previous radical mastectomy without preservation of pectoralis major 
muscle. Thanks to the development of modified radical mastectomy and 
to avoid some side effects of the sub-cutaneous procedures, like capsular 
contracture and prosthesis extrusion, during 1981, Gruber advocated 
the superiority of a sub-muscular (retro-pectoral) prosthesis recon-
struction versus the Snyderman’s procedure [31]. This important 
concept was also transferred to the TE approach performed by Argenta 
[32]. Nonetheless, a pre-pectoral sub-cutaneous approach was still 
claimed as the best option even later by Artz [33], when immediate 
two-steps PBBR was becoming quite popular. From this time 
(1988–1990), the sub-cutaneous technique eventually lost its initial 
appeal and for more than two decades almost disappeared as a choice of 
breast reconstruction. Implant coverage by a muscular pocket to inter-
pose a viable cushion in case of skin flap/wound dehiscence and to 
allegedly prevent capsular contracture has represented the most 
commonly utilized choice for many years so far. Very few articles of 
sub-cutaneous positioned implants and TE were published in the early 
XXI century [34,35]. Recently, with the adoption of soft tissue 
replacement devices, either biological or synthetic, identified as “sup-
portive materials”, the pure retro-pectoral trend has been modified, 
Table 3 
Safety profile and oncologic outcomes.    
N = 328 Percentage % SG CG Percentage % 
Early Complications No 285 86.9% 163 122 57.2% (SG) - 42.8% (CG)  
Yes 43 13.1% 29 14 67.4% (SG) - 32.6% (CG)  
Wound Dehiscence 8 2.4% 5 3 62.5% (SG) - 37.5% (CG)  
Hematoma 3 0.9% 1 2 33.3% (SG) - 66.7% (CG)  
Infection 24 7.3% 8 16 33.3% (SG) - 66.7% (CG)  
Skin-nipple necrosis 8 2.4% 5 3 62.5% (SG) - 37.5% (CG) 
Implant Removal No 313 95.4 185 128 59.1% (SG) - 40.9% (CG)  
Yes 15 4.6 7 8 46.7% (SG) - 53.3% (CG) 
Symmetrisation Immediate 14 4.3% 8 6 57.1% (SG) - 42.9% (CG)  
Delayed 36 11.0% 18 18 50.0% (SG) - 50.0% (CG)  
No 174 53.0% 99 75 56.9% (SG) - 43.1% (CG)  
Bilateral Mastectomy 104 31.7% 42 62 40.4% (SG) - 59.6% (CG) 
Second Look Fat Grafting (1) 53 16.2% 33 20 62.3% (SG) - 37.7% (CG)  
Fat Grafting (2) 7 2.1% 1 6 14.3% (SG) - 85.7% (CG)  
Fat Grafting (3) 1 0.3% 0 1 0% (SG) - 100% (CG)  
Implant Exchange 1 0.3% 0 1 0% (SG) - 100% (CG)  
Implant Exchange + Fat Grafting 3 0.9% 1 2 33.3% (SG) - 66.7% (CG)  
No Fat Grafting 257 78.4% 134 123 52.1% (SG) - 47.9% (CG)  
NAC Reconstruction + Fat Grafting 6 1.8% 2 4 33.3% (SG) - 66.7% (CG) 
Capsular contracture Grade IV 9 2.7% 1 8 11.1% (SG) - 88.9% (CG)  
Grade III 32 9.7% 4 28 12.5% (SG) - 87.5% (CG)  
Grade II 33 10% 10 23 30.3% (SG) - 69.7% (CG)  
Grade I 254 77.4% 110 144 43.3% (SG) - 56.7% (CG)  
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changing the choices in PBBR. A combined muscular-matrix pocket has 
become a very frequent option. The advantages offered by such devices 
were represented by an enlargement of the pocket and by the possibility 
to perform a definitive PBBR with an implant of right volume in a 
one-step surgery, so-called DTI. 
The use of these supportive materials allows a better lower pole and 
infra-mammary fold tailoring not in DTI alone, but also in two-step TE 
reconstruction. During the last years, the introduction of these sup-
portive materials has led to a completely novel approach consisting of a 
pre-pectoral prosthesis positioning, entirely covered by a biological or 
synthetic matrix, which is actually like “revisiting an old place” as 
several authors stated [36]. The rationale for a pre-pectoral recon-
struction performed with these supportive materials is to replicate the 
muscular coverage offered by major pectoralis muscle during a 
retro-pectoral approach. Such devices, in fact, proved to be safe when 
positioned under the mastectomy cutaneous flap in the lower lateral 
pole, in the aforementioned dual-plane technique, and, hence, where 
mechanical stress forces are highest. Therefore, the idea of a full 
coverage extended to all prosthetic surfaces rapidly emerged. Thus, 
these devices may replicate, in a pre-pectoral and sub-cutaneous 
approach, the same coverage effect of muscles in the retro-pectoral 
technique, without any muscular detachment, offering an even more 
natural result. Additionally, it is necessary to highlight, that a 
pre-pectoral approach in PBBR is minimally invasive (very less invasive 
than the retro-pectoral approach), leaving all muscles intact and there-
fore allowing any future strategy change. Thanks to the fact that the 
muscles are intact, it will be possible, in fact, where necessary, to 
perform a sub-muscular reconstruction or even adopt an autologous flap 
option. Additionally, one of the greatest advantages of the pre-pectoral 
approach is the reduction of post-operative pain and the risk of anima-
tion deformity. 
Nonetheless, in some cases, there is still some drawback to be faced 
in the pre-pectoral approach, which is, sometimes, an insufficient 
coverage thickness on the upper pole, avoided by pectoralis muscle, 
during the sub-muscular approach. This might lead to a visible 
Table 4 
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prosthesis border and some moderate rippling on the upper profile 
(identified as “Wrinkling"). 
This drawback may be determined by the different thicknesses of 
supportive material versus major pectoralis muscle, and it may be more 
evident especially when the skin flap is very thin. 
The study of Casella et al. [19] reported the immediate and long-term 
surgical and BREAST-Q results of 179 patients who underwent a mas-
tectomy and immediate reconstruction with TiLoop® Bra mesh (com-
parable to TCPM). In this report, based on DTI muscle-sparing 
sub-cutaneous reconstruction, the prosthesis was entirely wrapped 
within a TCPM bag and positioned under the skin flap, following con-
servative mastectomy. The 2-year results of QoL, measured by the 
BREAST-Q questionnaire, confirmed high patients’ satisfaction 
following mastectomy and TiLoop® immediate reconstruction. 
From another point of view, several concerns have been displayed by 
oncological-breast surgeons on the pre-pectoral approach and, in 
particular, on performing mastectomy with thick skin flaps, which could 
reduce the oncologic radicality of the procedure in an attempt to save as 
much more tissue as possible. On this issue, the authors of the present 
work in agreement with the data of the previous study published by 
Casella et al. [19] and others as Woo et al. [36], confirm that each 
mastectomy has to be performed following the plane of dissection at the 
level of Cooper’s ligament (the only one correct plane of dissection in 
mastectomy procedures) removing all grossly visible breast tissue, 
including the sub-areolar breast tissue in case of NSM, aside from the 
thickness of skin flaps. Only this must be considered as an oncologically 
safe mastectomy procedure. 
In the present work, the local tumor recurrence rate was 5.8% 
including three recurrences in the NAC (1,9%), two recurrences in 
axillary lymph-nodes (1,3%), three recurrences in skin flap (1,9%) and 
one recurrence (0,7%) in the muscle. In detail, the recurrence rate in the 
NAC (1,9%) appears to be in line with the literature and several 
important papers published by Galimberti et al. [37] and Lanitis et al. 
[2] reporting a recurrence rate in the NAC of 0–3.8%, and 0–3.7% 
respectively. On the other hand, a problem relating to the evaluation of 
“supportive materials”, especially about post-operative complication 
rates and proper patient selection is represented by the type of studies 
conducted, mainly represented by “single clinical trials” with a limited 
number of patients. Only recently Masià et al. [38] in a multicentric 
retrospective audit, collected the experience of 30 centers on 
pre-pectoral breast reconstruction with Braxton porcine ADM (Braxon; 
DECOmed Srl, Venice, Italy). A total of 1450 procedures, carried out by 
wrapping the implant with a pre-shaped porcine ADM, were retrospec-
tively collected in a period of six years. In this study, diabetes, smoke, 
and immunosuppression had an influence on complications occurrence, 
as well as implant weight. Capsular contracture was associated with 
adjuvant radiotherapy, also if the overall percentage was low (2.1%). 
Complications led to implant loss in 6.5% of the cases. In agreement 
with the above-mentioned results, the study of Onesti et al. [39] 
confirmed the low rate of postoperative complications, using the same 
porcine ADM. 
Additionally, there is still no consensus on whether synthetic 
matrices or biological matrices produce the best outcomes. In a review of 
Logan Ellis et al. [40], there were analyses of the differences in aesthetic 
outcomes, cost, and the rates of the most commonly reported compli-
cations. Here, the results display that TCPM synthetic mesh acts as 
bioactive material, producing breast reconstruction with remarkable 
aesthetic outcomes, with lower costs and complication rates. 
The individual results for complication rates show that biological 
matrices are associated with lower infection rates and slightly lower 
Fig. 2. 40 years old female patient who underwent bilateral SRM with Nipple Sparing, DTI immediate reconstruction positioning the prosthesis wrapped with TCPM 
in the pre-pectoral plane, and re-grafting of NAC according to Thorek technique (Intra-surgical view was shown in Fig. 1. A). 3/4 left pre-operative view. B) Pre- 
operative in frontal view. The breasts appear to be voluminous (macromastia) and with high-grade ptosis (pendulous breasts). C) 3/4 right pre-operative view. 
D) 3/4 left postoperative view after 2 years. E) Post-operative in frontal view, 2 years after the conservative mastectomy, pre-pectoral DTI, and TCPM mesh assisted 
reconstruction. The breast appears symmetric and with a good aesthetic outcome. F) 3/4 right post-operative view after the same time. 
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capsular contracture, but higher hematoma rates, and slightly higher 
rates of skin necrosis and explanation—although many had post-op 
radiotherapy. 
De Vita et al. [42] confirmed the absence of major side effects and 
excellent aesthetic outcomes performing IBR with pre-pectoral approach 
using polyurethane-coated implant, concluding this method represents a 
feasible alternative to subpectoral implant placement as confirmed also 
in very recent works published by Franceschini et al. [43] and Salgarello 
et al. [44]. On the other hand, it appears also pivotal analyze the cost of 
these procedures performing an economic evaluation. 
A treatment’ economic evaluation (defined as a comparative analysis 
of alternative courses of action in terms of both their costs and conse-
quences) primarily serves as a pragmatic aid to decision making [45]. 
Drummond et al. [45], highlights that the economic evaluation only 
addresses one dimension of treatment decision and that questions 
related to efficacy, effectiveness, and availability should be answered 
before an economic evaluation takes place. 
An accurate “cost-analysis” of these treatments, based on supportive 
materials use, have been performed by several authors. In particular, 
Karp et al. [46], performed a retrospective review on all consecutive 
Fig. 3. Histological analysis of TCPM mesh incorporation in breast soft tissue. A) Graphical reproduction of breast soft tissue anatomy, with focus on each layer; B) 
Hematoxylin-eosin image of post-operative biopsy of breast tissue involved in mesh graft; C) Capsule with TCPM mesh fully integrated; D) Magnification 4x inset of 
breast tissue directly harvested where the mesh was placed; collagen and fibroblast are identified, additionally, physiological restitutio ad integrum is observed. 
Fig. 4. Histological analysis of TCPM mesh incorporation in breast soft tissue. A) Hematoxylin and eosin stain of post-operative punch biopsy of breast tissue 
involved in TCPM mesh graft; B) Magnification 4x inset of image A) in which it is possible to distinguish different layers containing collagen, abundant capillaries 
sprout, fibroblasts, and in particular the layer of adipocytes in which it will be possible to perform fat grafting to improve the volume and aesthetic outcomes. 
Complete healing and newly deposed dermal collagen. 
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pre-pectoral one-stage breast reconstructions using ADM and synthetic 
mesh at a single institution. Several information as mastectomy type, 
reconstruction specs, results obtained, and supportive materials costs 
were analyzed. Calculated cost savings of synthetic mesh and ADM was 
up to $3415 in unilateral and $6830 in bilateral cases. Karp et al. [46], 
concluded the pre-pectoral breast reconstruction using ADM inferiorly 
and synthetic mesh superiorly was a safe technique that decreased 
material costs associated with support materials and allowed the plastic 
surgeon to precisely control the implant pocket and position. 
Additionally, should be specified that DTI (one stage procedure) is 
more affordable than TE requiring two stages procedures. 
5. Conclusions 
Based on the data reported so far in this paper, it is possible to affirm 
from present study that conservative mastectomies as NSM and SRM are 
oncologically safe, provided that patients are carefully selected. These 
procedures when associated with immediate DTI reconstruction with 
the pre-pectoral approach and mesh use, not only preserve breast 
appearance immediately but also provides the opportunity for remod-
eling breast profile, possibly using fat graft besides, further enhancing 
women appearance. Concluding, six points must be highlighted: 
Fig. 5. Double Immunofluorescence with CD 45 and Collagen 1. A) and B) images of TCPM mesh in a patient who underwent radiotherapy. The green color indicates 
collagen type 1, red color indicates Collagen type 3, with Nuclei contrasted in blue (DAPI staining). Red arrows indicated the lymphocytes. C) and D) immuno-
fluorescence imaging of a patient who didn’t undergo radiotherapy and TCPM use. 
Fig. 6. Immunohistochemistry using CD 45 on paraffin samples. A) 4x magnification and B) Imaging of TCPM mesh in a patient who underwent radiotherapy. Red 
arrows indicated the lymphocytes while blue arrows indicate fibroblasts. 
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1. Conservative mastectomies with pre-pectoral reconstruction must be 
considered oncologically safe in patients carefully selected;  
2. The association of NSM and SRM with DTI reconstruction consents to 
have a single one-step surgery of conservative mastectomy and im-
mediate reconstruction in large ptotic breasts;  
3. Pre-pectoral sub-cutaneous DTI reconstruction is less invasive than 
retro-pectoral (sub-muscular) approach because the muscles are left 
intact; 
4. The use of TCPM mesh in pre-pectoral sub-cutaneous DTI recon-
struction is safe and replicates in many and selected cases a pros-
thesis coverage similar to the major pectoralis muscle, with 
distinguished self-reported QoL assessment scores.  
5. The histological analysis of fragments of implant’s wrapping tissue 
incorporating TCPM mesh displayed complete incorporation of the 
mesh with physiological aspects of healing.  
6. The immunochemistry concluded the Collagen 1, and 3 expressions 
did not differ, with no statistical significance, between TCPM and NO 
TCPM samples, showing a process of physiological healing entailing 
a perfect device incorporation and confirming that TCPM is a 
bioactive material. 
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